Steven Pieper - 30 Jan 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Chief Financial Officer
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 30 Jan 2026
Net transactions value: -$1,512,730
Form type: 4
Filing time: 02 Feb 2026, 18:12:20 UTC
Previous filing: 03 Feb 2025
Next filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pieper Steven	Chief Financial Officer	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	02 Feb 2026	0001875714

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+154,986	+11%	$0.000000	1,572,547	30 Jan 2026	Direct	F1
transaction	XERS	Common Stock	Tax liability	$822,590	-111,765	-7.1%	$7.36	1,460,782	31 Jan 2026	Direct	F2
transaction	XERS	Common Stock	Tax liability	$489,072	-66,450	-4.5%	$7.36	1,394,332	31 Jan 2026	Direct	F2
transaction	XERS	Common Stock	Tax liability	$201,068	-27,319	-2%	$7.36	1,367,013	31 Jan 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XERS	Stock Option (Right to Buy)	Award	$0	+207,207		$0.000000	207,207	30 Jan 2026	Common Stock	207,207	$7.36	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
F2	Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
F3	These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Financial Officer